Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26358219 | 0.80 | CHRM5 (0.41) | CHRM5CHRM3SIGMAR1SMN1; SMN2HSD17B10 | |
| SCHEMBL20037943 | 0.79 | CHRM5 (0.35) | CHRM5CHRM3 | |
| SCHEMBL21574025 | 0.76 | KDM4E (0.44) | SMN1; SMN2HSD17B10 | |
| SCHEMBL20037995 | 0.75 | CHRM5 (0.35) | CHRM5CHRM3SIGMAR1 | |
| SCHEMBL18970190 | 0.74 | CHRM5 (0.40) | CHRM5CHRM3SIGMAR1SMN1; SMN2HSD17B10 | |
| SCHEMBL7228712 | 0.74 | CHRM5 (0.46) | CHRM5CHRM3SIGMAR1SMN1; SMN2HSD17B10 | |
| SCHEMBL4364895 | 0.73 | CHRM5 (0.50) | CHRM5CHRM3SIGMAR1 | |
| SCHEMBL22110045 | 0.73 | — | — | |
| SCHEMBL22110185 | 0.73 | KMT2A (0.35) | — | |
| SCHEMBL20038018 | 0.72 | MAPT (0.46) | CHRM5CHRM3SIGMAR1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4098647-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | Onecuregen Co., Ltd. (KR) | 2022-12-07 | — | — | EP | disclosed |